Benign Breast Disease In Women Research Articles

Effects of Melatonin Supplementation on Clinical Symptoms and Paraclinical Outcomes in Women Diagnosed With Fibrocystic Breast Disease: An Interventional Study

Fibrocystic breast disease is the most common benign breast disease in women, and it is necessary to investigate the most effective treatment method to reduce its symptoms. Therefore, the study was conducted to investigate the effect of melatonin supplementation on clinical symptoms and paraclinical outcomes in women diagnosed with fibrocystic breast disease. Investigating the Effects of melatonin supplementation on clinical symptoms and paraclinical outcomes in women diagnosed with fibrocystic breast disease. The present study is a controlled intervention-placebo treatment conducted on women suffering from fibrocystic breast disease aged 18-40. This interventional study was conducted on 66 patients (33 in the intervention group and 33 in the control group). Melatonin supplement of 3 mg was administered to the intervention group and a placebo to the control group for 12 weeks. Patient information, symptoms, and paraclinical outcomes were recorded at the beginning of the study before the intervention and 12 weeks after the intervention. After collecting the data, we analyzed it using SPSS version 16 software and appropriate statistical tests. The findings of this study showed that melatonin administration in patients with fibrocystic breast disease reduced anxiety, depression, improved sleep quality, increased TAC (Total Antioxidant Capacity), and decreased MDA (Malondialdehyde). However, both study groups did not have statistically significant differences in the average pain and hs-CRP before and after the intervention. According to the findings of the study and the identification of the positive effect of melatonin on laboratory indicators and symptoms in patients with fibrocystic breast disease, it is recommended to prescribe melatonin in addition to standard treatment to witness a better and faster recovery, and in this way, the quality of life of patients can be increased.

Abstract PO5-07-08: A Serum Biomarker for the Early Detection of Breast cancer

Abstract Background: After decades of use, clinicians and medical societies are still debating on the clinical utility of mammography, the standard of care for breast cancer (BC) screening, because of its limitations such as subjective visual interpretation, high rate of false-positive and false-negative (in dense breast) and concerns over radiation exposure. There are 55 million women, and about 45% of them considered dense breast, in need of an accurate, easy to use test for the screening of BC regardless of breast tissue complexities to differentiate between BC and benign findings such as calcification and fibrosis. To this date there is no blood protein biomarker (BM) in clinical use for the early detection of BC. We have developed a novel BC specific protein biomarker -based blood test to detect patients with early-stage BC and established herein the diagnostic performance of our BM in discriminating BC patients from healthy individuals and benign breast cases. Methods: A total of 433 serum samples (318 primary BC, 32 benign breast and 83 normal breast) were obtained from the Cooperative Human Tissue Network and from the IRCCS San Raffaele Pisana Research Center (blind samples). 247 BC samples were provided as blind samples and were used to validate the screening utility. Serum samples were tested with our BC specific BM by sandwich ELISA. Receiver operating characteristic (ROC) curves were calculated to evaluate the diagnostic performance, by determining sensitivity (SE), specificity (SP), area under the curve (AUC), and confidence interval (CI). Statistical analysis, ROC curves and scatter plots were performed with GraphPad Prism 7.0. Results: BM elevation in early cancer cases (stage I-II, Ductal Carcinoma) was found to be statistically significant (p< 0.0001) as compared to healthy and benign cases. Our test discriminated early BC patients from non-cancer cases with 87.3% SE at 85.2% SP and was further validated in a blind set including 247 BC (Ductal & Lobular Carcinoma, stage I-III), 30 benign and 83 normal breast cases (88%SE, 86%SP). The sensitivity for early-stage (I-II) and late stage (III) BC was 86.8% and 94.3%, respectively. While lobular carcinoma is particularly not well detected by mammography with a sensitivity as low as 57% and much lower for women with dense breast, it was detected with high sensitivity (90%) in our test. 80% of fibrocystic changes (FCC), the most common form of benign breast disease in women over 50 years of age were negative with our test. Although it is a benign condition, FCC may be misdiagnosed as a malignant lesion by physical examination and imaging. Conclusion: Our results support the utility of our blood-based test for the early detection of breast cancer which presents improved features over mammography such as higher lobular cancer sensitivity, lower detection rate of common form of benign condition often misdiagnosed by imaging, absence of radiation and expected high compliance. Further testing is needed to confirm accuracy of our test in the dense breast population. Citation Format: Christine Chavany, Jeffrey Dea, Monica Guevara, Rafael Hernandez-Gonzalez, Patrizia Ferroni, Fiorella Guadagni, Rosaura Valle, Moncef Jendoubi. A Serum Biomarker for the Early Detection of Breast cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO5-07-08.

Evaluation of benign breast diseases.

Objectives: To find the frequency of benign breast diseases presented to outdoor patient department and to exclude malignancy. Study Design: Descriptive Case Series Study. Setting: Department of General Surgery, Hayatabad Medical Complex, Peshawar. Period: July 2021 to June 2022. Material & Methods: Ninety five females presented to OPD with complaints of breast pain, lumpy, nipple and breast discharge. All patients were investigated through triple assessment. Mammography and trucat biopsy were performed in selected cases. Diagnosed cases of breast cancer and those picked up through investigations, were excluded. Data was analyzed through SPSS. Results: The age range was 11 years to 71 years with a mean age of 28 years (SD ± 7.55 years). Forty three (45.3%) patients presented in the 3rd decade, followed by 26 (27.4%) in the 2nd decade of life. The most common conditions encountered were fibroadenoma in 42.17% (n=40) cases, mainly in 3rd decade. Inflammatory conditions like acute mastitis and abscess formation was found in 21.05% (n=20) Cases. Fifteen (15.8%) patients had fibrocystic diseases, in the 3rd and 4th decades. Conclusion: Fibroadenoma is the commonly encountered benign breast disease in women in the 3rd decade. FNAC is a quick and reliable investigation to exclude malignancy and relieve mental stress in women.

Circulating miRNAs as Novel Non-Invasive Biomarkers to Aid the Early Diagnosis of Suspicious Breast Lesions for Which Biopsy Is Recommended.

Simple SummaryIn population-based screens, tissue biopsy remains the standard practice for women with imaging that suggests breast cancer. We examined circulating microRNAs as minimally invasive diagnostic biomarkers to discriminate malignant from benign breast lesions. A retrospective cohort of plasma samples divided into training and testing sets and a prospective cohort of women with suspicious imaging findings who underwent tissue biopsy were investigated through a global microRNA profile by OpenArray. Seven signatures, involving 5 specific miRNAs (miR-625, miR-423-5p, miR-370-3p, miR-181c, and miR-301b), were identified and validated in the testing set. Among the 7 signatures, the discriminatory performances of 5 of them were confirmed in the prospective cohort.In population-based screens, tissue biopsy remains the standard practice for women with imaging that suggests breast cancer. We examined circulating microRNAs as minimally invasive diagnostic biomarkers to discriminate malignant from benign breast lesions. miRNAs were analyzed by OpenArray in a retrospective cohort of plasma samples including 100 patients with malignant (T), 89 benign disease (B), and 99 healthy donors (HD) divided into training and testing sets and a prospective cohort (BABE) of 289 women with suspicious imaging findings who underwent tissue biopsy. miRNAs associated with disease status were identified by univariate analysis and then combined into signatures by multivariate logistic regression models. By combining 16 miRNAs differentially expressed in the T vs. HD comparison, 26 signatures were also able to significantly discriminate T from B disease. Seven of them, involving 5 specific miRNAs (miR-625, miR-423-5p, miR-370-3p, miR-181c, and miR-301b), were statistically validated in the testing set. Among the 7 signatures, the discriminatory performances of 5 were confirmed in the prospective BABE Cohort. This study identified 5 circulating miRNAs that, properly combined, distinguish malignant from benign breast disease in women with a high likelihood of malignancy.

Characterizing benign breast disease in women at high risk for breast cancer.

1506 Background: Benign breast disease (BBD) is an established risk factor for breast cancer, with the highest risk associated with atypical proliferative subtypes. In the general population, atypical hyperplasia (AH) is associated with a 20-50% increase in invasive breast cancer risk persisting at least 25 years post biopsy. Limited information exists on the prevalence and characteristics of BBD in women at high risk for breast cancer. Methods: In an ongoing prospective study of women with a family history of breast cancer and/or a BRCA1/2 mutation who attend the Breast and Ovarian Surveillance Service (BOSS) at Johns Hopkins (n = 953), we identified 575 women who reported having at least one breast surgical procedure at the time of enrollment. 66% of these women had 2 or more relatives with breast and/or ovarian cancer. 257 breast cancer cases and 170 cases of incident BBD were subsequently confirmed based on pathology report. Slides were then obtained for re-review and evaluation of specific histologic...

Abstract A75: DNA repair genotypes associated with benign breast disease in women at high breast cancer risk

Abstract A75 Background Benign breast disease (BBD) is a risk factor for breast cancer and may have a heritable component. Little is known about genetic factors associated with BBD risk. Deficient DNA repair has been implicated in the etiology of breast cancer. Since DNA repair occurs early in the breast carcinogenesis pathway, it is logical that polymorphic forms of DNA repair genes may alter BBD risk. No prior studies have reported on the association between DNA repair variants and BBD. Methods We examined the association between a panel of DNA repair genotypes and BBD in a sub-cohort of women within CLUE II, a population based cohort study in Washington County, Maryland. The women were followed from 1989 to 2003 with biennial questionnaires from 1996 onwards eliciting information on many health outcomes, including physician diagnosis of BBD and breast biopsies. 3,212 women reporting no prior diagnosis of BBD at baseline were genotyped for non-synonymous SNPs in 8 DNA repair genes (ERCC2, ERCC4, ERCC5, RAD23B, XPC, XRCC1, XRCC2, and XRCC4) that had previously been implicated in cancer risk. BBD-free survival time was fitted to age-adjusted Cox proportional hazards model and analyzed by DNA repair genotype. Results Carriers of the variant alleles of XRCC1 codon 194 and ERCC4 codon 415 were significantly more likely to be diagnosed with BBD than non-carriers -- hazard ratios (HR) = 1.36, 95%CI 1.06-1.74 and 1.39, 95%CI 1.09-1.76, respectively. The association between the ERCC4 variant and BBD was even greater among women with a positive family history of breast cancer. In this subgroup, the variant ERCC4 allele was associated with a 2.7 fold increase in breast cancer risk (HR = 2.63, 95% CI 1.52-4.66, p interaction = 0.02). Conclusion Variant ERCC4 and XRCC1 genotypes are significantly associated with a diagnosis of BBD in this population, particularly in women with a family history of breast cancer. These same genes have also been implicated in the risk of breast cancer in other studies. Taken together, these studies support the notion that these two DNA repair genes may have a common role in the etiology of both BBD and breast cancer. Citation Information: Cancer Prev Res 2008;1(7 Suppl):A75.

The prevalence of benign breast disease in women with polycystic ovary syndrome: a review of a 12-year follow-up

A cross-sectional study of benign breast disease (BBD) was conducted to determine the actual prevalence and follow-up importance of BBD among women with polycystic ovary syndrome (PCOS) in conjunction with an ongoing prospective cohort study. The present study involved a subset of the original group of 244 women with a diagnosis of PCOS and 244 control women matched by age and race. A total of 240 women (116 cases and 124 controls) were included in the present analysis. The majority of women in each group were Caucasians (93 and 96%, respectively). The median age was 46 years in the cases and 47 years in the controls. Screening mammography begins at the age of 40 and has been carried out in 69% of cases and 66% of controls since the study began. Family history of breast disease was observed in 27 cases of both the groups (p > 0.05). Neither fibrocystic breast disease, lump thickening, calcification, fibroadenoma, pain, redness, discharge nor hyperplasia showed a significantly higher prevalence rate in cases than in controls. Eleven (9%) women with PCOS and 21 (17%) controls underwent diagnostic or curative surgery (relative risk: 0.56). These results, in contrast to the previously published literature, do not allow us to conclude that there is a higher risk for BBD among women with PCOS, and the proportion of women with a positive family history of breast cancer was significantly greater in women with PCOS compared with controls. Our observation is that having PCOS does not appear to affect surgeons' decisions to remove BBD.

Effects of tamoxifen on benign breast disease in women at high risk for breast cancer.

In 1998 the National Surgical Adjuvant Breast and Bowel Project (NSABP) demonstrated that tamoxifen treatment reduced the incidence of both invasive and noninvasive breast cancer in women at high risk for the disease. We examined the effect of tamoxifen treatment on the incidence of benign breast disease and the number of breast biopsies in the same group of women. We examined the medical records of 13 203 women with follow-up who participated in the NSABP Breast Cancer Prevention Trial. Included in this analysis were women who had undergone a breast biopsy and who had histologic diagnoses of adenosis, cyst, duct ectasia, fibrocystic disease, fibroadenoma, fibrosis, hyperplasia, or metaplasia. The relative risk (RR) for each histologic diagnosis was estimated for women who received tamoxifen and for women who received placebo. We also tallied the number of biopsies that women in the placebo and tamoxifen groups underwent. Overall, tamoxifen treatment reduced the risk of benign breast disease by 28% (RR = 0.72, 95% confidence interval [CI] = 0.65 to 0.79). Tamoxifen therapy resulted in statistically significant reductions in the risk of adenosis (RR = 0.59, 95% CI = 0.47 to 0.73), cyst (RR = 0.66, 95% CI = 0.58 to 0.75), duct ectasia (RR = 0.72, 95% CI = 0.53 to 0.97), fibrocystic disease (RR = 0.67, 95% CI = 0.58 to 0.77), hyperplasia (RR = 0.60, 95% CI = 0.50 to 0.71), and metaplasia (RR = 0.51, 95% CI = 0.41 to 0.62). Tamoxifen therapy also reduced the risk for fibroadenoma (RR = 0.77, 95% CI = 0.56 to 1.04) and fibrosis (RR = 0.86, 95% CI = 0.72 to 1.03). Compared with the placebo group, the tamoxifen group had 29% (95% CI = 23% to 34%) fewer biopsies (1048 versus 1469) and 19% fewer women who underwent a biopsy (811 versus 1019). This resulted in a 29% reduction in the risk of biopsy in women treated with tamoxifen (RR = 0.71, 95% CI = 0.66 to 0.77). This risk reduction occurred predominantly in women younger than 50 years. Women in this study who received tamoxifen, especially younger women (i.e., <50 years), had a reduced incidence of clinically detected benign breast disease and underwent fewer breast biopsies.

The Role of the Breast Clinic Nurse

Women scheduled for breast biopsy procedures experience heightened anxiety about the outcomes of their diagnostic procedures. Perioperative nurses have unique opportunities to provide quality nursing care for patients awaiting breast biopsy procedures and their definitive diagnoses. The prevalence (ie, 50%) of benign breast disease in women of reproductive age and the anxiety related to the threat of breast cancer are important nursing concerns. This article addresses the breast clinic nurse's role in meeting the emotional and informational needs of women scheduled for breast biopsy procedures. The human response to illness (HRI) model is used as a framework for understanding the phenomenon of anxiety within this context. The HRI model provides a basis for delivering quality nursing care through the development of an enhanced role for the breast clinic nurse.

Caffeine and Benign Breast Disease

<h3>To the Editor.—</h3> The recent study on caffeine and benign breast disease (BBD) requires further comment. Lubin et al¹conclude that "our findings suggest that there is no association between coffee consumption and BBD." They also state that their results are consistent with two earlier reports by Lawson et al²and Marshall et al³and refer to their own article and the latter two as "all case-control studies." The authors note, however, that several clinical studies have found an improvement in BBD in women who restrict their intake of methylxanthines. Lubin et al neglected to cite a previous case-control study involving 634 women with fibrocystic disease and 1,066 controls. Boyle et al⁴found a 1.5-fold increase in the risk of BBD for women consuming 31 mg to 250 mg of caffeine per day, and a 2.3-fold risk for women drinking over 500 mg a day. Notably,

Benign breast disease in women on estrogen therapy

Benign breast disease in women on estrogen therapy

Benign breast disease in women on estrogen therapy. A pathologic study.

Breast tissue has been examined from 43 women taking estrogens for menopausal symptoms or post-menopausal replacement therapy. Two of the patients had typical fibroadenomas. Tissue from the remaining patients presented the spectrum of fibrocystic disease. Slides from these 41 cases were coded and mixed with slides from age-matched patients with fibrocystic disease who denied hormone usage. A variety of epithelial patterns were tabulated without knowing the status of hormone usage. The patients taking estrogens had a slightly greater frequency of epithelial hyperplasia (39%) compared to the controls (32%). No qualitative differences were detected between the 2 groups and the slight variation in frequency of hyperplasia is judged to be insignificant.